Abstract

specifically diagnostic of schizophrenia; and the few treatments available are only partially effective, and only in a subset of patients. Corvin looks to a future in which diagnosis will be guided by molecular etiology, and patients may be treated with drugs known to be effective for the particular genetic subtype of disease. One of the most striking findings of the genetic studies is that individual rare mutations of large effect often confer susceptibility to more than one disorder, for example both schizophrenia and autism. Overlap in susceptibility is also seen in the GWAS that have to date identified 10 common variants with small effects on disease risk, though here the major overlap is seen with bipolar disorder. These findings are consistent with epidemiological studies that indicate shared risk for different disorders, and families in which a spectrum of disorders is observed. The strong association of different disorders with the same mutation suggests they can be distinct phenotypic endpoints that can arise from a common genetic origin, rather than a polygenic effect, a possibility that can be explored using the modeling approach outlined by Mitchell and colleagues. Corvin concludes from this accumulating evidence that schizophrenia will not continue to be viewed as a single disease. In one respect there is a notable difference in the stance taken by the two articles. Mitchell and coauthors espouse the proposition, gaining ground of late [3, 4], that the disease-associated rare variants reported so far (mostly short deletions or duplications) represent only the tip of the iceberg, and that as sequencing studies uncover more functionally relevant mutations, most cases of neuropsychiatric disease will be found to be attributable, in large part, to single rare mutations of large effect. Corvin on the other hand takes the view that with only 5% of cases so far explained by rare mutations, it is too early to judge to what extent they account for the heritability of the disease, and that the combined effect of common alleles, together with environmental factors, may still explain a considerable fraction of cases [5]. These two different outlooks reflect a lively and ongoing debate on

Highlights

  • Psychiatric disorders affect approximately 1 in 4 people

  • This thinking has been challenged by recent findings of an increasing number of rare mutations that have a large effect on disease susceptibility

  • In their review article [1], Kevin Mitchell, Josh Huang, Bita Moghaddam and Akira Sawa lay out a framework for studying the effects of these rare variants in animals, explaining why they see this as the best way to model psychiatric disease

Read more

Summary

Introduction

Psychiatric disorders affect approximately 1 in 4 people. Two articles published today in BMC Biology [1,2] discuss prospects for an improved understanding of their biology and treatment, informed by recent and ongoing advances in defining the genetic architecture that underlies them. This thinking has been challenged by recent findings of an increasing number of rare mutations that have a large effect on disease susceptibility.

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.